MEBT/MEBO联合自体中厚皮移植治疗足趾电烧伤1例报告

目的观察皮肤再生医疗技术(moist exposed burn therapy/moist exposed burn ointment,MEBT/MEBO)联合自体中厚皮移植治疗足趾电烧伤的临床疗效。方法对2010年3月福安市医院外科收治的1例足趾高压电烧伤患者在皮肤减张术后采用MEBT/MEBO治疗,待创面肉芽组织生长良好后予以自体中厚皮移植治疗,观察治疗效果。结果治疗45 d后,创面愈合,患者出院;出院后随访3个月,创面愈合良好,愈后皮肤无明显瘢痕增生及功能障碍。结论 MEBT/MEBO联合自体中厚皮移植治疗足趾电烧伤,可有效促进创面愈合,预防足趾瘢痕增生及功能障碍,避免截趾,且操作简便,值得临床推广应用。     

Pregnancy after a TRAM flap procedure: principles of nursing care

Breast cancer is the most common malignancy in women in the United States and affects more than 200,000 women annually. The incidence increases exponentially with age from the 3rd to the 5th decade of life. Many women are now choosing to have a more natural breast reconstruction concomitantly with their mastectomy. A TRAM (transverse rectus abdominis myocutaneous) flap is a procedure to reconstruct the breast mound using autologous tissue. Women of childbearing age who have undergone a TRAM flap may safely consider pregnancy after such a procedure. The principles of nursing care for pregnant women who have undergone a TRAM flap surgery are presented in this article. A case report of pregnancy after a TRAM flap is included.     

自体脂肪颗粒移植治疗声带沟

目的探讨自体脂肪颗粒移植治疗声带沟的疗效。方法对32例声带沟患者采用改良的自体脂肪颗粒移植技术进行治疗。自体脂肪颗粒注射移植1—2次,中间间隔3—6个月。通过术前、术后声门裂隙及患侧声带表面积,以及患者自我感觉等随访,评价其治疗效果。结果最长4．5年,平均2．5年的随访发现在1～2次自体脂肪注射后,脂肪可以在受区长期存活。78．13％以上的患者对疗效满意,小于9．38％的患者对疗效不满意。结论自体脂肪移植技术用于声带沟是一项安全而有效的治疗方法。     

动脉药物灌注联合干细胞动脉移植治疗股骨头缺血性坏死的临床研究

目的探讨动脉药物灌注联合自体骨髓间充质干细胞动脉移植治疗股骨头缺血坏死的疗效。方法收集2009年1月～2011年2月在我科接受自体骨髓间充质干细胞移植的75例（共126髋）股骨头缺血性坏死的患者,采用经皮股动脉穿刺将导管超选至股骨头供血动脉,先灌注罂粟碱30ml、尿激酶50万u、复方丹参30ml,最后将骨髓间充质干细胞悬液等量注入各支血管。术后第3、6、12、18、24个月,根据成人股骨头缺血坏死修复与再造评价标准评价疗效,影像学评价股骨头形态学变化。结果疼痛缓解率95．65％（118／126）;步行距离延长84％（63／75）;关节功能缓解率8650％（109／126）;影像学改善率72．73％（56／77）。结论经动脉药物灌注联合自体骨髓间充质干细胞动脉移植治疗股骨头缺血性坏死介入治疗方法简便、安全有效,能够有效的治疗股骨头缺血性坏死。     

体外循环自体血预充技术对全身炎性反应的影响

目的 研究体外循环采用自体血预充技术对全身炎性反应相关指标的影响.方法 32例非急诊手术首次接受体外循环下心脏冠脉搭桥的患者,依性别（男女比例）、年龄、体重、身高、体表面积（BSA）和射血分数（EF）进行配对后分为两组：自体血预充组（16例）和经典预充组（16例）.自体血预充组：用1250 ml晶体液和8000 IU肝素预充,体外循环开始前先采用自体血预充技术置换出大部分最初预充液,置换过程中严密监视血流动力学变化,维持平均动脉压（MAP）在50 mm Hg以上.整个过程依患者血流动力学耐受程度决定.经典预充组：1250 ml晶体液和8000 IU肝素预充.两组患者心肌保护均采用Calafiore温血停跳液灌注,体外循环中保持温度35.0 ℃～35.5 ℃,流量 2.5～2.8 L·min-1·m-2.所有患者按标准手术步骤进行手术,先完成全部远端吻合口后,开放升主动脉再逐一完成近端吻合.平均体外循环时间64 min,阻断升主动脉时间37 min,平均每例搭桥3.0支.手术结束前将体外循环系统中余血全部回输给患者.结果 自体血预充组平均置换出（885±161）ml的最初预充液,患者体外循环中、手术结束时、术后6 h、术后1 d的HCT水平均明显高于经典预充组（P＜0.05）.90%自体血预充组患者围术期免于输血,而经典预充组患者未输血比例为68%.患者体外循环结束和体外循环后6 h动脉血IL-6水平低于经典体外循环组（P＜0.05）.经典预充组患者体外循环开始和结束时IL-8、TNF-α水平高于自体血预充组（P＜0.05）.结论 体外循环应用自体血预充技术能减少血液稀释,减少围术期输血量,一定程度地抑制IL-6、IL-8和TNF-α炎症介质的升高.     

Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy

Objective/BackgroundPatients with follicular lymphoma (FL) with early therapy failure (ETF) within 2 years of frontline therapy have poor overall survival (OS). We recently reported the results of autologous stem cell transplantation (ASCT) in patients from the Grupo Español de Linfomas y Trasplantes de Médula Ósea (GELTAMO) registry treated with rituximab prior to ASCT and with ETF after first-line immunochemotherapy, leading to 81% 5-year OS since ASCT. We explored whether ASCT is also an effective option in the pre-rituximab era—that is, in patients treated in induction and rescued only with chemotherapy.MethodsETF was defined as relapse/progression within 2 years of starting first-line therapy. We identified two groups: the ETF cohort (n = 87) and the non-ETF cohort (n = 47 patients receiving ASCT but not experiencing ETF following first-line therapy).ResultsThere was a significant difference in 5-year progression-free survival between the ETF and non-ETF cohorts (43% vs. 57%, respectively; p = .048). Nevertheless, in patients with ETF with an interval from first relapse after primary treatment to ASCT of <1 year, no differences were observed in 5-year progression-free survival (48% vs. 66%, respectively; p = .44) or in 5-year OS (69% vs. 77%, p = .4). Patients in the ETF cohort transplanted in complete remission showed a plateau in the OS curves, at 56%, beyond 13.7 years of follow-up.ConclusionASCT may be a curative option for ETF in patients who respond to rescue chemotherapy, without the need for immunotherapy or other therapies, and should be considered as an early consolidation, especially in patients with difficult access to rituximab.     

Intraoperative cell salvage versus postoperative autologous blood transfusion in hip arthroplasty: a retrospective service evaluation

INTRODUCTION

A number of ways of reducing blood loss in arthroplasty have been explored, including preoperative autologous transfusion, intraoperative cell salvage and postoperative autologous transfusions. Both intraoperative blood salvage and postoperative retransfusion drains have been shown to be effective in reducing blood loss in total hip arthroplasty. In our department there was a change in practice from using postoperative retransfusion drains to intraoperative cell salvage. To our knowledge no study has directly compared using intraoperative blood salvage and postoperative retransfusion drains alone in total hip arthroplasty.

METHODS

This was a retrospective service evaluation including all primary hip arthroplasty performed under our care between January 2006 and December 2008. Patients were divided into two groups: Group A used a postoperative autologous blood transfusion (ABT) drain and Group B used intraoperative cell salvage.

RESULTS

A total of 144 patients were included in this study: 84 in Group A and 60 in Group B. The mean haemoglobin difference for Group A was 3.96g/dl (standard deviation [SD]: 1.52) and for Group B it was 3.46g/dl (SD: 1.42). The mean haematocrit difference for Group A was 0.12% (SD: 0.05) and for Group B it was 0.10% (SD: 0.04). Using an independent t-test for the comparison of means, a significant difference was found between Group A and B both in regards to haemoglobin difference (p=0.009) and haematocrit difference (p=0.046).

CONCLUSIONS

We feel that intraoperative cell salvage provides a more efficient method of reducing blood loss than postoperative retransfusion in primary total hip replacement. A prospective randomised study would be useful to ascertain any clinical difference between the two methods.